Amazing results! More de risking for Efti.
Who knows why they are panicking over there, probably sell the news. But these results really confirm and enhance Efti as a treatment in key patients sub groups. We are taking a significant proportion of MBC patients. Which means big bucks! It also further enhances Efti as a treatment in general.
”Survival benefit of +7.5 months, +19.6 months and +4.2 months in the < 65 years, low monocytes and luminal B subgroups, respectively. Reflects a benefit of > 50%, > 150% and > 33%, respectively.”
I imagine the FDA and EMA will be very happy with these results. And Efti is safe.
Forget the panic selling these results are excellent for the future of Efti and Immutep.
Go long and stay strong
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results, page-7
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $459.4K | 1.254M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 133642 | 8 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |